Holen Sie sich die Stockscreener-App
83.45
0.82%
-0.69
Handel nachbörslich:
84.32
0.87
+1.04%
Intra Cellular Therapies Inc Aktie (ITCI) Neueste Nachrichten
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Intra-Cellular Therapies' SWOT analysis: CAPLYTA drives stock potential amid patent challenges - Investing.com India
Intra-Cellular Therapies' SWOT analysis: CAPLYTA drives stock potential amid patent challenges By Investing.com - Investing.com South Africa
Geode Capital Management LLC Increases Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
S&P 500 Futures Drop in Premarket Trading; Intra-Cellular Therapies, Avantor Lag - Barron's
Franklin Resources Inc. Purchases 155,655 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
(ITCI) Technical Pivots with Risk Controls - Stock Traders Daily
State Street Corp Has $136.02 Million Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Y Intercept Hong Kong Ltd Trims Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies' SWOT analysis: Caplyta's success drives stock potential - Investing.com
Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting - The Manila Times
Intra-Cellular Therapies Presents Data from the CAPLYTA - GlobeNewswire
Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College - EIN News
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Holdings Decreased by Wellington Management Group LLP - MarketBeat
Intra-Cellular Therapies: Parkinson's Disease Drug Expansion Could Be The Next Huge Move - Seeking Alpha
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by BNP Paribas Financial Markets - MarketBeat
Insider Selling: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) CEO Sells 51,000 Shares of Stock - MarketBeat
Intra-cellular Therapies CEO sells $8.72 million in stock By Investing.com - Investing.com UK
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 11,104 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD - MSN
Study Estimates 5 Million People Could Benefit from Magic Mushrooms for Depression Treatment - Managed Healthcare Executive
(ITCI) Investment Analysis and Advice - Stock Traders Daily
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by Parkman Healthcare Partners LLC - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Bank of Montreal Can - MarketBeat
Loss-Making Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Expected To Breakeven In The Medium-Term - Simply Wall St
HighVista Strategies LLC Has $548,000 Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Erste Asset Management GmbH Purchases Shares of 23,400 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies Seeks FDA Approval for Caplyta as Additional Treatment for Depression - Managed Healthcare Executive
Intra-Cellular Eyes Depression Approval for Caplyta as Stock Flies Under the Radar - BioSpace
Intra-Cellular Ther (ITCI-Q) QuotePress Release - The Globe and Mail
Point72 Hong Kong Ltd Sells 38,075 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy - The Manila Times
Intra-Cellular Therapies Submits Supplemental New Drug - GlobeNewswire
Intra-Cellular Therapies Says FDA Approved Caplyta to Treat Bipolar Depression, Shares up - Marketscreener.com
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Acquired by Bellevue Group AG - MarketBeat
Point72 Europe London LLP Lowers Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
54,629 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Purchased by Edgestream Partners L.P. - MarketBeat
Cerity Partners LLC Has $3.23 Million Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies stock rated Outperform by Mizuho, with 13% stock rise post-earnings - Investing.com UK
Why Is Intra-Cellular (ITCI) Up 2.2% Since Last Earnings Report? - Yahoo Finance
Vestal Point Capital LP Makes New Investment in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Suvretta Capital Management LLC Has $105.29 Million Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stake Decreased by Charles Schwab Investment Management Inc. - MarketBeat
Fmr LLC Sells 116,146 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
How Intra-Cellular surprised Wall Street by breaking character - BioPharma Dive
Cynosure Group LLC Purchases 8,909 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Makes New Investment in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Algert Global LLC Reduces Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Natixis Advisors LLC Has $1.80 Million Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Analysts Set Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Target Price at $97.23 - MarketBeat
Westfield Capital Management Co. LP Increases Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Trend Tracker for (ITCI) - Stock Traders Daily
2.89%
1.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):